✦ LIBER ✦

5001 CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer (MBC)

✍ Scribed by M. Martin; S. Hurvitz; J. Kennedy; J. Forbes; H. Roché; T. Pinter; W. Eiermann; M. Buyse; M. Rupin; J. Mackey

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase II Trial of weekly pacl

✍ Giampietro Gasparini; Massimo Gion; Luigi Mariani; Paola Papaldo; Diana Crivella 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 222 KB

A Phase II Trial of Docetaxel With Bevac

✍ Sara A. Hurvitz; Heather J. Allen; Rebecca L. Moroose; David Chan; Christopher H 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 598 KB

The efficacy of bevacizumab plus paclita

✍ Wang, Xuan; Huang, Chun; Li, Man; Gu, Yanjun; Cui, Yanfen; Li, Yan 📂 Article 📅 2014 🏛 S. Karger AG 🌐 English ⚖ 395 KB

2098 ORAL BCIRG 007: First overall survi

✍ T. Pienkowski; M. Pegram; J. Forbes; V. Valero; W. Eiermann; G. Von Minckwitz; M 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 77 KB

446 PUBLICATION A phase II trial of tras

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Comment on Wang et al.: The efficacy of

✍ Li, Jun; Yao, Yunfeng; Jing, Juehua 📂 Article 📅 2014 🏛 S. Karger AG 🌐 English ⚖ 74 KB